However, durable responses have been uncommon to date.
However, despite a high Initials response rate, durable responses are rare.
However, despite the initial success of ICB-treatment, still a minority of patients experience durable responses to ICB therapy.
These agents have led to strikingly durable responses in several of these solid tumors, but their efficacy has been inconsistent.
On the other hand, the modern immunotherapy strategies have been associated with durable responses but in limited number of patients.
We hypothesized that combining targeted therapy with immunotherapy could result in more patients with responses and/or more durable responses.
Induction of more potent and durable responses may require new adjuvants or replicating chimeric vectors chimeras that bear HIV genes.
Therapy with ipilimumab leads to durable responses.
Furthermore, durable responses are achievable with the same-agent maintenance.
However, most of the patients did not have durable responses.
However, these combinations do not appear to produce more durable responses than cytokines alone [ 19– 24].
